49594-75-4

Basic information

• Product Name: 3-(4-ETHYLBENZOYL)PROPIONIC ACID
• Synonyms: 4-(4-ETHYLPHENYL)-4-OXOBUTANOIC ACID;4-(4-ETHYLPHENYL)-4-OXOBUTYRIC ACID;3-(4-ETHYLBENZOYL)PROPIONIC ACID;4-(4-ETHYLPHENYL)-4-OXOBUTYRIC ACID 95%;4-(4-ethylphenyl)-4-keto-butyric acid;Benzenebutanoic acid, 4-ethyl-.gamma.-oxo-;Maybridge1_002070;NSC246068
• CAS NO: 49594-75-4
• Molecular Formula: C₁₂H₁₄O₃
• Molecular Weight: 206.24
• Mol File: 49594-75-4.mol
• Article Data: 19

Chemical Properties

• Melting Point: 92-94°C
• Boiling Point: 398.6°Cat760mmHg
• Flash Point: 209°C
• Appearance: /
• Density: 1.136g/cm³
• Vapor Pressure: 4.56E-07mmHg at 25°C
• CAS DataBase Reference: 3-(4-ETHYLBENZOYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-ETHYLBENZOYL)PROPIONIC ACID(49594-75-4)
• EPA Substance Registry System: 3-(4-ETHYLBENZOYL)PROPIONIC ACID(49594-75-4)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 49594-75-4(Hazardous Substances Data)

Usage

Uses

4-Ethyl-γ-oxobenzenebutanoic Acid is a useful reagent in preparation of 1,8-naphthyridinyl-3(2H)-pyridazinones in dry media under microwave irradiation using zeolite-HY supported on silica gel catalyst.

InChI:InChI=1/C12H14O3/c1-2-9-3-5-10(6-4-9)11(13)7-8-12(14)15/h3-6H,2,7-8H2,1H3,(H,14,15)/p-1

Upstream product

• 108-30-5 succinic acid anhydride 
• 100-41-4 ethylbenzene 
• 100-42-5 styrene 
• 543-20-4 succinoyl dichloride 
• 103-73-1 Phenetole 

Downstream Products

• 5467-53-8 γ-(p-ethylphenyl)butyric acid 
• 56705-44-3 methyl 4-(4-ethylphenyl)-4-oxobutanoate 
• 854676-64-5 4-(4-ethyl-phenyl)-3-bromo-4-oxo-butyric acid 
• 132659-70-2 3-[5-(4-ethyl-phenyl)-2-oxo-furan-3-ylidene]-2,3-dihydro-isoindol-1-one 
• 117808-88-5 3-(4-ethylbenzoyl)-3-butenoic acid 
• 64637-12-3 3-[1-Benzo[1,3]dioxol-5-yl-meth-(E)-ylidene]-5-(4-ethyl-phenyl)-3H-furan-2-one 
• 124-38-9 carbon dioxide 
• 619-64-7 p-ethylbenzoic acid 
• 49594-80-1 1-(4-ethylphenyl)prop-2-en-1-one 
• 55901-91-2 6-(ethylphenyl)-2,3,4,5 tetrahydropyridazine-3-one 
• 511311-09-4 5-(4-Ethyl-phenyl)-3-[1-thiophen-2-yl-meth-(E)-ylidene]-3H-furan-2-one 
• 692728-83-9 4-(4-chloro-benzyl)-7-ethyl-3,4-dihydro-2H-naphthalen-1-one 

Relevant articles and documents

In silico designing, in vitro and in vivo evaluation of potential PPAR-γ agonists derived from aryl propionic acid scaffold

Attributed to several side effects, especially on hepatic tissues and body weight, there is always an urge of innovation and upgrading in already existing medication being used in maintaining diabetic condition. Therefore, in the present work, forty-eight molecules derived from arylpropionic acid scaffold were synthesized and their evaluation against diabetes was carried out. The synthesis of these molecules attributed to excellent dock score displayed by all the structures performed against PPAR-γ receptor site. Subsequently, all the derivatives were primarily deduced for their antidiabetic potential by OGTT. The compounds that showed significant antidiabetic activity in OGT Test and also exhibited high dock scores were assessed further by in vitro PPAR transactivation assay to assure analogy between in vivo and in vitro studies. The antidiabetic activity of these active compounds was then evaluated on STZ induced diabetic model in vivo. The most active compounds were scrutinized for its effect on PPAR-γ gene expression and hepatotoxic effect. Finally, it was recapitulated that these derivatives can provide a new prospect towards the development of antidiabetic agents with fewer side effects.

Design, Synthesis, and Pharmacological Screening of Pyridazinone Hybrids as Anticonvulsant Agents

A series of new hybrid benzimidazole containing pyridazinones derivatives were designed and synthesized in accordance with the pharmacophoric requirements essential for the anticonvulsant activity. The synthesized compounds were evaluated for anticonvulsant activity on mice by the gold standard maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ)-induced seizure models. Among the compounds tested, SS-4F showed significant anticonvulsant activity in both the screens with ED50 values of 25.10 and 85.33 mg/kg in the MES and scPTZ screens, respectively. Compound SS-4F emerged as safer and effective anticonvulsant due to its several-fold higher protective indices. Further, the gamma-aminobutyric acid (GABA) estimation result showed a marked increase in the GABA level (1.7-fold) as compared to the control, which was further confirmed by good binding properties with the GABAA receptor.

Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives

Some new 7-substituted-phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine/one/thione derivatives were synthesized by a sequence of reactions starting from appropriate aryl hydrocarbons. The final compounds were screened for antihypertensive activities by non-invasive method using Tail Cuff method. All the test compounds showed significant antihypertensive activity; 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine (4p) exhibited antihypertensive activity more than the reference standard drugs.